Main results
Four trials and one abstract reporting on 481 patients were included in the systematic review. Quality of the included studies was good in three out of five included studies. For the three comparable studies on conventional cooling methods all authors provided individual patient data. With conventional cooling methods patients in the hypothermia group were more likely to reach a best cerebral performance categories score of one or two (CPC, five point scale; 1= good cerebral performance, to 5 = brain death) during hospital stay (individual patient data; RR, 1.55; 95% CI 1.22 to 1.96) and were more likely to survive to hospital discharge (individual patient data; RR, 1.35; 95% CI 1.10 to 1.65) compared to standard post-resuscitation care. Across all studies there was no significant difference in reported adverse events between hypothermia and control.
Authors' conclusions
Conventional cooling methods to induce mild therapeutic hypothermia seem to improve survival and neurologic outcome after cardiac arrest. Our review supports the current best medical practice as recommended by the International Resuscitation Guidelines.
P L A I N L A N G U A G E S U M M A R Y

Cooling the body after cardiac arrest
To date about one tenth to a third of successfully resuscitated patients leave hospital to live an independent life again. Clinical studies have shown that this outcome can be improved by cooling the body to about 33°C for several hours after cardiac arrest. We found five randomized trials with data on a total of 481 cardiac arrest survivors. With conventional cooling methods patients were more likely to leave hospital without major brain damage and they were more likely to survive to hospital discharge. No cooling specific adverse events were reported. In summary there is currently evidence supporting the use of conventional cooling to induce mild hypothermia in cardiac arrest survivors within the first hours of restoration of spontaneous circulation.
B A C K G R O U N D
The incidence of out-of-hospital sudden cardiac arrest in industrial countries is reported to be between 0.04% and 0.19% per year (Becker 1993; Rea 2004) . Of all patients where resuscitation was attempted, 14% to 40% achieved return of spontaneous circulation and were admitted to hospital (Finn 2001; Fischer 1997; Giraud 1996; Herlitz 2003b; Kuisma 1996; Leung 2001; Rewers 2000) . Of those patients admitted to hospital, only between 7% to 30% were discharged from hospital with good neurologic outcome (Absalom 1999; Böttiger 1999; Fischer 1997; Herlitz 1999; Jennings 2001; Westfal 1996; Weston 1997) .
Therapeutic hypothermia is still a relatively new concept for the preservation of cerebral function in patients who are resuscitated after cardiac arrest. After patients have been stabilized their body temperature is lowered to 32 to 34°C for a duration of 24 hours. It is believed that therapeutic hypothermia works in multiple ways. Cerebral reperfusion after successful resuscitation, although essential and effective in restoring energy stores, can also trigger harmful chemical cascades. The generation of free radicals and other mediators is responsible for the postresuscitation syndrome, which leads to multifocal damage of the brain (Negovsky 1988) . In contrast to accidental hypothermia, therapeutic mild hypothermia (32 to 34°C) is administered in a controlled way. During hypothermia the ability to survive anoxic no-flow states is dramatically increased (Ginsberg 1992) . Intra-ischaemic hypothermia for brain protection has been used for several years with certain surgical procedures and circulatory arrest states. Clinical and experimental results show a protective effect of hypothermia during but also after ischaemic situations (Rosomoff 1954) . Therapeutic hypothermia can inhibit the biosynthesis, release and uptake of several catecholamines and neurotransmitters (Boels 1985; Okuda 1986 ) especially glutamate and dopamine, which could lead to tissue damage (Busto 1989; Choi 1987; Globus 1987) . Other beneficial effects of hypothermia include the preservation of the blood brain barrier (Karibe 1994) , the protection of adenosine triphosphate (ATP) stores (Mizuhara 1996) , which are necessary for energy provision; the restitution of post ischaemic cerebral microcirculation (Takasu 1996) , and possibly also decreased intracranial pressure and increase cerebral blood flow (Marion 1997) . Subsequently, hypothermia reduces the amount of cell death in certain brain regions (Busto 1989b) and seems to act in a multifactorial way by influencing several damaging pathways simultaneously.
Postresuscitation care has developed many new concepts in the past few years aiming at improving neurological outcome and survival of patients after cardiac arrests. It comprises optimizing haemodynamics and ventilation, electrolytes, seizure control, temperature and glucose control and is summarized in the main resuscitation guidelines (AHA 2000; ERC 2005) .
Recently, two randomized controlled trials (RCTs) showed that induced hypothermia has a neuro protective effect in patients who are primarily resuscitated from cardiac arrest (Bernard 2002; HACA 2002) . A meta-analysis pooled the data of these two RCTs and the data of one additional feasibility study and showed a clear benefit in terms of neurologic outcome and survival with hypothermia treatment for patients successfully resuscitated after cardiac arrest (Holzer 2005) . Although recommended in the guidelines of the International Liaison committee on Resuscitation (ILCOR) (Nolan 2003) and the recent resuscitation guidelines (ERC 2005) , therapeutic hypothermia still is a relatively new concept. At the moment many different cooling methods exist: conventional cooling comprises extracorporeal methods with cooling pads, ice packs, water immersion or intravascular cooling with cooling catheters or simply cold fluids. Cooling can also be combined with haemofiltration or any extracorporeal cardiopulmonary support. Studies with different treatment modalities are emerging and therefore systematic and regular updates of the literature are important to monitor new and effective developments. We undertook this Cochrane review with a view to assembling the current literature.
O B J E C T I V E S
We aimed to perform a systematic review and meta-analysis to assess the effectiveness of therapeutic hypothermia in patients after cardiac arrest. Neurologic outcome, survival and adverse events were our main outcome parameters. We aimed to perform individual patient data analysis if data were available. We intended to form subgroups according to the cardiac arrest situation.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomized and "quasi randomized", controlled trials. "Quasi randomized" refers to allocation procedures such as alternating days, odd and even days, and the like.
Types of participants
We included studies in adult patients who suffered from cardiac arrest (regardless of in-hospital or out-of-hospital cardiac arrest) and were successfully resuscitated. We excluded studies on children and adolescents (aged less than 18 years) as the presumed cause of cardiac arrest is different to those in adults. Although patients with a prior neurologic history may not greatly benefit from the intervention, we did not exclude them for the following reasons:
1. the number of such patients most likely is negligible; and 2. in a real life situation information on neurological performance before the arrest is often not available when starting post-resuscitation therapy.
Types of interventions
The intervention of interest was therapeutic hypothermia, regardless of how body temperature was reduced, applied within six hours of arrival at hospital. We defined therapeutic as any body target temperature below 35°C. We defined the control intervention as treatment according to the standard treatment after cardiac arrest at the time of the trial.
Types of outcome measures
Primary outcomes
The primary outcome measure was neurological recovery. Ideally we expected the outcome to be reported as best neurologic outcome during hospital stay and in cerebral performance categories (CPC) (Cummins 1991; Jennett 1975) . The CPC categories are defined as follows.
1. Good cerebral performance: conscious, alert, capable of normal life. Normal cerebral function. May have minor psychological or neurological deficits, which do not significantly compromise cerebral or physical function.
2. Moderate cerebral disability: conscious, alert, sufficient cerebral function for activities of daily life (e.g. dress, travel by public transportation, food preparation). May have hemiplegia, seizures, ataxia, dysarthria, dysphasia, or permanent memory or mental changes.
3. Severe cerebral disability: conscious, has at least limited cognition. Dependant on others for daily life support (i.e., institutionalized or at home with exceptional family effort), because of impaired brain function. Includes wide range of cerebral abnormalities, from ambulatory patients who have severe memory disturbance or dementia precluding independent existence, to paralysed patients who can only communicate with their eyes (e.g. the locked-in syndrome).
4. Coma/vegetative state: not conscious, unaware of surroundings, no cognition. No verbal and/or psychological interaction with environment. May appear awake because of spontaneous eye opening or sleep-wake cycle. Includes all degrees of unresponsiveness, which are neither CPC three (conscious) nor CPC five (coma, which satisfies brain death criteria).
5. Certified brain death. If authors grouped this outcome into one or two (good recovery), and three to five (unfavourable recovery) we adapted it for our meta-analysis. If not reported in CPC categories we accepted when authors reported "good" neurologic outcome, which we assumed to be comparable with CPC score of one or two.
Secondary outcomes
Survival to hospital discharge, survival at six months and longterm, quality of life at six months and long-term, dependency, and cost-effectiveness. We defined long-term as a minimum of one year.
Adverse events
We aimed at reporting adverse events as given by the authors. . We did not apply any language restrictions. In an attempt to identify further studies we asked experts in the field whether they were aware of any ongoing, unpublished, or published trials on this subject. We performed the searches entering search terms as multiple postings (.mp, term appears in the title, abstract or MeSH) and some as medical subject headings (MeSH) for MEDLINE and exploded terms for EMBASE and CINAHL (search terms for CENTRAL, Appendix 1; MEDLINE, Appendix 2; EMBASE, Appendix 3; CINAHL, Appendix 4; BIO-SIS and PASCAL, Appendix 5). A search strategy for identifying RCTs was used with MEDLINE (Dickersin 1994) and EMBASE (Lefebvre 1996) . The search was completed on 25 January 2007.
Search methods for identification of studies
Data collection and analysis
Data extraction
We independently extracted data using a data extraction form (see Appendix 6).We imported all retrieved results into EndNote (version 7.0, Thomson Corporation) and eliminated duplicates. Two authors (JA, MH) independently scanned each reference for inclusion in the review. As we intended to use original individual patient data of the identified trials we contacted the respective corresponding author and asked for collaboration. Two authors independently entered all relevant data into The Cochrane Collaboration's software program Review Manager (RevMan 5). We compared the two versions and resolved disagreements by discussion. To assess the internal validity of the identified trials, we assessed allocation sequence generation, allocation concealment, blinding of outcome assessment, exclusion of randomized patients from the analysis, comparability of groups, and loss to follow up. The following variables were entered into RevMan 5:
1. allocated intervention; 2. event (best neurological recovery during hospital stay, survival to hospital discharge); 3. additional baseline variables: cause of cardiac arrest (presumed cardiac versus non-cardiac); location of arrest (inhospital versus out-of-hospital); witnessed versus non-witnessed arrest; primary ECG rhythm (ventricular fibrillation versus other).
Quantitative data synthesis
We assessed data for clinical and statistical heterogeneity. We only performed quantitative synthesis of the data if clinical heterogeneity was negligible. Clinical heterogeneity may be caused by differences in study populations, interventions or definitions of the endpoint (Thompson 2001) . In case of severe heterogeneity it may not be suitable to pool the data because the trials measure a different effect altogether.
Analysis at the individual level
Quantitative analysis of individual patient data was intended when studies had negligible heterogeneity and individual patient data was available at least for a clinically comparable subset. In the case that individual patient data were unavailable for at least one study, we planned to do an analysis at the study level. This applies in particular to further updates. We performed quantitative analysis of individual patient data using standard statistical procedures provided in RevMan 5. We calculated relative risks and their 95% confidence intervals. All analyses were according to the intentionto-treat principle. The principal measure of effect was the relative risk of achieving good neurological recovery defined as a best CPC category of one or two or the definition which was given by the author for "good neurologic outcome".
Analysis at the study level
Here also the principal measure of effect was the relative risk of achieving good neurological recovery in patients allocated to hypothermia when compared to those not receiving hypothermia at hospital discharge. In case of negligible statistical heterogeneity we used fixed-effect models to calculate summary effects, otherwise we used random-effects models. Statistical heterogeneity was assessed using the I 2 statistic (Higgins 2003). Statistical heterogeneity was considered relevant if I 2 was > 50%.
Subgroup analyses
For the primary endpoint we formed subgroups using the individual patient data according to the following variables:
• cause of cardiac arrest (presumed cardiac versus noncardiac);
• location of arrest (in-hospital versus out-of-hospital);
• witnessed versus non-witnessed arrest;
• primary ECG rhythm (ventricular fibrillation versus other)
Sensitivity analysis
We performed sensitivity analyses for the impact of study quality issues as measured by allocation concealment on the overall effect estimate and the effect size of all identified trials neglecting heterogeneity and publication status.
Publication bias
We assessed the presence of possible publication bias and heterogeneity using funnel plots (plotting the effect against precision) (Egger 1997).
R E S U L T S Description of studies
See: Characteristics of included studies; Characteristics of excluded studies; Characteristics of studies awaiting classification. Our systematic search of databases of the medical literature resulted in 1353 hits. From those we excluded 242 duplicates;1092 further papers were excluded according to our eligibility criteria (randomized studies on adult cardiac arrest patients treated with therapeutic hypothermia, neurologic recovery as outcome) by judging the abstract or the title. Nineteen papers remained for closer inspection. From those we excluded two feasibility studies, four studies that were reviews, one report on the published RCTs of therapeutic hypothermia after cardiac arrest, three studies that used historical controls, and five studies that turned out to be comments or editorials (see Characteristics of excluded studies and Figure 1 ). 
Clinical heterogeneity
We identified clinical heterogeneity due to cooling methods. In contrast to the other studies, Laurent 2005 used haemofiltration as mode of cooling which is substantially different to the standard cooling methods used in the other RCTs. As the cooling method of Mori 2000 was unclear, we presented this study separately and did not pool the effect with those of the remaining studies. For the three comparable studies on conventional cooling methods all authors provided individual patient data (Bernard 2002; HACA 2002; Hachimi-Idrissi 2001) .
Risk of bias in included studies
We assessed each included trial by the following criteria: mode of randomization, allocation concealment, level of blinding, loss to follow up, comparability of groups and use of measures to account for differences between groups. Quality of the included studies was good in three out of five studies. Three trials (HACA 2002; Hachimi-Idrissi 2001; Laurent 2005) reported adequate randomization methods and the use of opaque envelopes to conceal treatment allocation. Three trials reported blinded outcome assessment (Bernard 2002; HACA 2002; Hachimi-Idrissi 2001) . One study lost information for two patients for the primary endpoint (HACA 2002) . All other studies had a complete follow-up. In two studies treatment and control group did not differ significantly in reported baseline characteristics (Hachimi-Idrissi 2001; Laurent 2005) while one of these had rather small groups (Hachimi-Idrissi 2001). In HACA 2002 there were some baseline differences between groups. Patients in the normothermia group were more likely to have a history of diabetes mellitus or coronary heart disease and to have received basic life support from a bystander than were those in the hypothermia group. The authors adjusted for all baseline variables and the risk ratio increased slightly, from 1.40 (95% confidence interval (CI) 1.08 to 1.81) to 1.47 (95% CI 1.09 to 1.82). Bernard 2002 reported differences in sex and rate of bystander cardiopulmonary resuscitation between groups but did not further adjust for this possible bias. Mori 2000 did not provide information on baseline characteristics of the patient groups.
Effects of interventions Primary outcome
Good neurologic outcome
With only three studies reporting on conventional cooling methods (involving 195 cases and 188 controls), the pooled result showed better survival for the hypothermia group (individual patient data; RR, 1.55; 95% CI 1.22 to 1.96; I 2 = 32%; see Analysis 1.1.1).
As there was only one study for patients undergoing haemofiltration after cardiac arrest (Laurent 2005), it was not possible to employ meta-analysis. Using the data in the study, however, and carrying out a chi-squared statistic we found no statistical difference (Pearson chi 2 statistic = 0.16 P = 0.69; RR, 0.71; 95% CI 0.32 to 1.54; see Analysis 1.1.2). The one study reporting on an unknown cooling method (Mori 2000) showed better survival for the hypothermia group (Pearson chi 2 = 7.78, P = 0.005; RR, 4.50; 95% CI 1.17 to 17.30; see Analysis 1.1.3.).
Secondary Outcomes
Survival to hospital discharge
With only three studies reporting on conventional cooling methods (involving 195 cases and 188 controls), the pooled result showed better survival for the hypothermia group (individual patient data; RR, 1.35; 95% CI 1.10 to 1.65; I 2 = 0%; see Analysis 2.1.1).
As there was only one study for patients undergoing haemofiltration after cardiac arrest (Laurent 2005) the chi 2 statistic found that there was no statistical difference ( Pearson chi 2 = 0.77, P = 0.38; RR, 0.71; 95% CI 0.32 to 1.54; see Analysis 2.1.2).
Survival at 6 months and long-term
We found no data on this outcome.
Quality of life at 6 months and long-term dependency
Cost effectiveness
Subgroup Analyses
According to the number of patients and information provided by the authors we formed subgroups of the meta-analysis by the following parameters: cause of cardiac arrest (presumed cardiac versus non-cardiac), location of arrest (in-hospital versus out-of-hospital); witnessed versus non-witnessed arrest, primary ECG rhythm (ventricular fibrillation (VF/VT) versus other). The endpoint was "best ever reached CPC during hospital stay" (see Additional Table  1 ). • The effect size for patients with a cardiac cause (three studies) and VF/VT was nearly the same (two studies)
• Groups of patients with non-VF/VT rhythm as first cardiac rhythm (n = 52), and patients with a non-cardiac cause (n = 11), and in-hospital arrests (n = 17) were small and did not show a statistically significant effect (non-VF/VT: RR 2.17; 95% CI 0.68 to 6.93; I 2 = 50%; two studies; non-cardiac cause RR 3.80; 95% CI 0.55 to 26.29; I 2 = 0%; two studies; in-hospital: RR, 1.67; 95% CI 0.47 to 5.73)
• Also a small number of patients had non-witnessed arrest (n = 22). Among these patients the effect size was substantially bigger than the summary effect for the whole study population (RR 5.31; 95% CI 1.40 to 20.21; I 2 = 0%; three studies)
• For patients with witnessed cardiac arrest the effect size was slightly smaller than the effect size for the whole study population (RR 1.43; 95% CI 1.13 to 1.81; I 2 = 0%; three studies)
Long-term outcome, cost-effectiveness, and quality of life
None of the retrieved studies provided data on long term survival and dependency, quality of life, or cost-effectiveness.
Adverse events
We included all trials that reported on adverse events in the analysis, regardless of heterogeneity. The following adverse events were reported in the four studies: bleeding of any severity, need for platelet transfusions, pneumonia, sepsis, pancreatitis, renal failure or oliguria, haemodialysis, pulmonary oedema, seizures, lethal or long lasting arrhythmias, cardiac complications, hypocalcaemia, and hypophosphataemia. There were no significant differences between the groups (see Additional Table 2 ). 
Sensitivity Analysis
Does allocation concealment influence the effect? For studies using conventional cooling methods, cooling had a favourable effect on good neurological outcome in studies with adequate allocation concealment. This effect, however, was significant in a fixed-effect model (RR 1.50; 95% CI 1.16 to 1.93; see Additional Table 3 ) but not significant in a random-effects model (RR 1.97; 95% CI 0.71, 5.45 ). This result comes from two studies which showed both a significant and positive effect, but there was statistical heterogeneity (I 2 = 59%), and total sample size comprised only 306 patients. 
Publication bias
At the moment there are too few studies to draw inferences from funnel plots, we have therefore not presented them in the current version of this review.
D I S C U S S I O N
Quality of evidence
We found five studies on the application of mild hypothermia with a total of 481 patients (Bernard 2002; HACA 2002; Hachimi-Idrissi 2001; Laurent 2005; Mori 2000) . All studies were academia initiated. Quality of the studies was generally good. Except for the abstract (Mori 2000) , all studies reported on almost all essential quality criteria and loss to follow up was within an acceptable range. One study could have done better on the randomization process and the adjustment for inequalities in baseline characteristics between the treatment and the control group (Bernard 2002).
After our literature search we were able to include the data of all eligible studies we retrieved. Table 1 ). However, the group of non-witnessed arrests was small (22 patients only) and yielded large confidence intervals. Although it seems that patients benefit from the treatment, the result should be interpreted with caution.
One of the problems with merging the data for this review was the difference in the inclusion criteria. Generally among all patients that are resuscitated and brought to hospital, between 18% and 42% have non-witnessed arrests, only 30% to 58% a confirmed VF rhythm as first rhythm (Herlitz 2003a; Haukoos 2004; Kim 2001) , 40% of all resuscitations happen in hospital. In this review the two bigger studies included only patients with cardiac cause of cardiac arrest, and with VF/VT-rhythm as first cardiac rhythm (Bernard 2002; HACA 2002) . Most of these patients had out-of-hospital cardiac arrest. From the pathogenesis of global cerebral ischaemia and the theories as to why therapeutic hypothermia is effective, there is no reason why therapeutic hypothermia should not be as effective in patients with asystole as first cardiac rhythm or noncardiac causes for cardiac arrest. In a meta-analysis (Holzer 2005) the effect of therapeutic hypothermia was only sightly changed by baseline variables. A retrospective cohort study showed that the effect of therapeutic hypothermia was independent of various confounders including cardiac arrest conditions (Arrich 2006). The major limitation of this review is the small number of randomized controlled trials and hence small numbers of included patients. Therefore the precision of our effects is generally low, and particularly in subgroup and sensitivity analyses this is a matter for concern. The confidence intervals of the intervention come near the null difference and looking at studies with adequate allocation concealment resulted in an effect which was not robust to model choice in our sensitivity analysis. On the other hand only two studies have been included in the sensitivity analysis which is probably too small to make firm conclusions. Nonetheless, given these limitations the effect of conventional cooling methods consistently points towards a favourable neurological outcome. Another consequence of the small number of available studies are the many single study comparisons.
One might argue that therapeutic hypothermia is only available to countries with sufficient financial resources. But there are many cooling methods ranging from expensive device controlled methods to very cheap cold fluids and ice packs which are available in all facilities where post-resuscitation care is performed. Proof of superiority of any cooling method above others is still lacking, and there are currently no formal cost-benefit analyses.
Main results
Our review shows that therapeutic hypothermia with conventional cooling methods improves neurologic outcome and survival of patients successfully resuscitated after cardiac arrest. Currently available evidence suggests that patients with out-of-hospital cardiac arrest, a presumed cardiac cause of cardiac arrest and for patients with a VF/VT rhythm as first recorded cardiac rhythm benefit from therapeutic hypothermia. For patients with in-hospital cardiac arrest, asystole and non-cardiac causes of arrest the group sizes are too small to make firm inferences. There were no statistically significant differences in any of the reported adverse events between hypothermia and non-hypothermia patients.
What does this review contribute?
After the publication of the two RCTs on therapeutic hypothermia, (Bernard 2002; HACA 2002) guidelines by the International Liaison Committee on Resuscitation (ILCOR) on the application of therapeutic hypothermia after cardiac arrest were published (Nolan 2003) . Despite a small number of included trials and patients the results of our review support those recommendations.
A U T H O R S ' C O N C L U S I O N S Implications for practice
Implications for research
Future research should be done with standardized temperature monitoring (either oesophagus or bladder temperature measurements) in order to be able to compare between groups and between studies at a later stage. Effective measures need to be advanced to cool the patient to the target temperature within a short time period which should decrease heterogeneity within the study population. For studies with a focus on out-of-hospital cooling, practical methods need to be evaluated. To further investigate the effect of cooling on subgroups, like patients with a non-VF/VT as primary cardiac rhythm, or patients with in-hospital cardiac arrest, methodologically sound studies are needed. There is a knowledge gap concerning an optimal cooling protocol. For this purpose inclusion criteria should be widened and comparisons of earlier cooling (pre-hospital) versus late cooling (in-hospital), different levels of hypothermia (e.g. 32°C versus 34°C), and different durations of cooling (e.g. 12 hours versus 24 hours versus 48 hours) should be included. Safety reporting should not only comprise the known but any unexpected adverse events. It would be useful to include cost benefit analyses in future studies.
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